The role of CRP and inflammation in the pathogenesis of age-related macular degeneration;Uloga CRP i upale u patogenezi makularne degeneracije povezane sa starošću

Biochemia Medica

Volumn 22, Issue 1, 2012, Pages 39-48

  Colak, Emina ^a   Majkic Singh, Nada ^a   Zoric, Lepsa ^a   Radosavljevic, Aleksandra ^a   Kosanovic Jakovic, Natalija ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Age related macular degeneration; C reactive protein; Inflammation

Indexed keywords

7 OXOCHOLESTEROL; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANTIOXIDANT; C REACTIVE PROTEIN; CHOLESTEROL; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OMEGA 3 FATTY ACID; REACTIVE OXYGEN METABOLITE;

ATHEROSCLEROSIS; BINDING SITE; BLINDNESS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUSEN; EUROPEAN AMERICAN; FISH; GENDER; GENETIC PREDISPOSITION; HUMAN; INFLAMMATION; LEISURE; MACROPHAGE; OXIDATIVE STRESS; PIGMENT EPITHELIUM; RETINA BLOOD FLOW; RETINA MACULA AGE RELATED DEGENERATION; RETINITIS PIGMENTOSA; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING CESSATION;

EID: 84857020438     PISSN: 13300962     EISSN: None     Source Type: Journal    
DOI: 10.11613/bm.2012.005     Document Type: Review

References (91)

1. Gu J, Pauer GJT, Yue X, Narendra U, Sturgill GM, Bena J, et al. Proteomic and Genomic Biomarkers for Age-Related Macular Degeneration. Adv Exp Med Biol 2010;664:411-7.
2. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-4.
3. Nowak J. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep 2006;58:353-63.
4. McGwin G, Hall TA, Xie A, Owsley C. The regulation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study. Br J Ophthalmol 2005;89:1166-70.
5. Seddon J, Gensler G, Milton R, Klein ML, Rifai N. Association between C-reactive protein and age-related macular degeneration. JAMA 2004;291:704-10.
6. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614.
7. Coleman HR, Chan CC, Ferris FL, Chew EY. Age-related macular degeneration. Lancet 2008;372:1835-45.
8. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 2001;108:697-704.
9. Klein R, Klein BE, Jenson SC, Mares-Perlman JA, Cruickshanks KJ, Palta M, et al. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology 1999;106:1056-65.
10. Hu DN, Simon JD, Sarna T. Role of ocular melanin in ophthalmic physiology and pathology. Photochem & Photobiol 2008;84:639-44.
11. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-9.
12. Yates YR, Sepp T, Matharu BK. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007;357:19-27.
13. O'Shea JG. Age-related macular degeneration. Postgrad Med J 1998;74:203-7.
14. Tomany SC, Wang JJ, van Leeuwen R, Klein R, Mitchell P, Vingerling JR, et al. Risk factors for incident age-related macular degeneration. Pooled findings from 3 continents. Ophthalmology 2004;111:1280-7.
15. Mares-Perlman JA, Brady WE, Klein R, VandenLangenberg GM, Klein BE, Palta M. Dietary fat and age-related maculopathy. Arch Ophthalmol 1995;113:743-8.
16. Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease, and age-related macular degeneration. Arch Ophthalmol 2000;118:351-8.
17. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 2001;119:1417-36.
18. SanGiovanni JP, Chew EY, Clemons TE, Davis MD, Ferris FL 3rd, Gensler GR, et al. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study. Arch Ophthalmol 2007;125:671-9.
19. Winkler BS, Boulton ME, Gottsch JD, Sternberg P. Oxidative damage and age-related macular degeneration. Molecular Vision 1999;5:32-45.
20. Klein R, Klein BE, Jensen SC, Cruickshanks KJ. The relationship of ocular factors to the incidence and progression of agerelated maculopathy. Arch Ophthalmol 1998;116:506-13.
21. Klein R, Klein BE, Jensen SC, Cruickshanks KJ. Sunlight and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 2001;119:246-50.
22. Chakravarthy U, Wong TY, Fletcher A, Piault E, Evans C, Zlateva G, et al. Clinical risk factors for age-related macular degeneration: A systemic review and meta-analysis. BMC Ophthalmol 2010;10:31.
23. Choi JK, Lym YL, Moon JW, Shin HJ, Cho B. Diabetes mellitus and early age-related macular degeneration. Arch Ophthalmol 2011; 129:196-9.
24. Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and long-term incidence of age. related macular degeneration: the Blur Mountains Eye Study. Ophthalmology 2007;114:1143-50.
25. Bourla DH, Young TA. Age-Related Macular Degeneration:a practical approuch to a challenging disease. J Am Geriatr Soc 2006;54:1130-5.
26. Bressler SB. Introduction: Understanding the Role of Angiogenesis and Antiangiogenic Agents in Age-Related Macular Degeneration. Ophthalmology 2009;116:S1-7.
27. Yuan A, Kaiser PK. Emerging therapies for the treatment of neovascular age related macular degeneration. Semin Ophthalmol 2011;26:149-55.
28. McLeod DS, Taomoto M, Otsuji T, Green WR, Sunness JS, Lutty GA. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 2002;43:1986-93.
29. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A potential role for immune complex pathogenesis in drusen formation. Exp Eye Res 2000;70:441-9.
30. Nagaoka T, Kuo L, Ren Y, Yoshida A, Hein TW. C-reactive protein inhibits endothelium-dependent nitric oxide-mediated dilatation of retinal arterioles via enhanced superoxide production. Invest Ophthalmol Vis Sci 2008;49:2053-60.
31. Simundic AM. New insights in the pathophysiology of inflammation. Biochem Med 2011;21:243-4.
32. Thiruvagounder M, Khan S, Sheriff DS. The prevalence of metabolic syndrome in a local population in India. Biochem Med 2010;20:249-52.
33. Mueck AO, Seeger H, Wallwiener D. Further evidence for direct vascular actions of statins: effect on endothelial nitric oxide synthase and adhesion molecules. Exp Clin Endocrinol Diabetes 2001;109:181-3.
34. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003;290:2945-51.
35. Chase HP, Cooper S, Osberg I, Stene LC, Barriga K, Norris J, et al. Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes 2004;53:2569-73.
36. Yasukawa T. Inflammation in age-related macular degeneration: pathological or physiological? Expert Rev Ophthalmol 2009;4:107-12.
37. van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: The Rotterdam Study. Invest Ophthalmol Vis Sci 2003;44:3771-7.
38. Boekhoom SS, Vingerling JR, Witteman JC, Hofman A, de Jong P. C-reactive protein level and risk of aging macula disorder: The Rotterdam Study. Arch Ophthalmol 2007;125:1396-401.
39. Van der Meer IM, de Maat MP, Bots ML, Breteler MM, Meijer J, Kiliaan AJ, et al. Inflammatory mediators and cell adhesion molecules as indicators of severity of atherosclerosis: The Rotterdam Study. Arterioscler Thromb Vasc Biol 2002;22:838-42.
40. Jovicic S, Ignjatovic S, Dajak M, Kangrga R, Majkic-Singh N. Factor analysis of cardiovascular risk determinants associated with elevated C-Reactive protein concentraction. J Med Biochem 2010;29:447-8.
41. Ali A, Sultan P, El-Napoli M, Fahmy MA. Lipoprotein metabolism abnormalities in patients with chronic renal insuffi-ciency. J Med Biochem 2011;30:38-44.
42. Penfold PL, Madigan MC, Gillies MC, Provis JM. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 2001;20:385-414.
43. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-31.
44. Roth F, Bindewald A, Holz FG. Key pathophysiologic pathways in age-related macular disease Graefes Arch Clin Exp Ophthalmol 2004;242:710-6.
45. Curcio CA, Johnson M, Huang JD, Rudolf M. Aging, age-related macular degeneration, and the response-to-retention of apolipoptotein B-containing lipoproteins. Prog Ret Eye Res 2009;28:393-422.
46. Ebrahimi KB, Handa JT. Lipids, lipoproteins and age-related macular degeneration. J Lipids 2011;2011:802059.
47. Olofsson SO, Boren J. Apolipoprotein B: a clinically important apolipoprotein which assembles atherogenic lipoproteins and promotes the development of atherosclerosis. J Int Med 2005;258:395-410.
48. Lommatzsch A, Hermans P, Muller KD, Bornfeld N, Bird AC, Pauleikhoff D. Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunohistochemical analysis of AMD associated with basal deposits. Gre Arch Clin Exp Ophthalmol 2008;246:803-10.
49. Picard E, Houssier M, Bujold K, Sapieha P, Lubell W, Dorfman A, et al. CD36 plays an important role in the clearance of oxLDL and associated age-dependent sub-retinal deposits. Aging 2010;2:981-9.
50. Srewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, et al. CD36 ligands promote sterile inflammation through assembly of a tool-like receptor 4 and 6 heterodimer. Nat Immunol 2010;11:155-61.
51. Chau KY, Sivaprasad S, Patel N, Donaldson TA, Luthert PJ, Chong NV. Plasma levels of matrix metalloproteinase-2 and-9 (MMP-2 and MMP-9) in age-related macular degeneration. Eye 2007;21:1511-5.
52. Verna S, Yeh ETH. C-reactive protein and atherotrombosis-Beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol 2003;285:R1253-6.
53. Kim SY, Sadda S, Pearlman J, Humayun MS, de Juan E Jr, Melia BM, Green WR. Morphometric analysis of the macula in eyes with disciform age-related macular degeneration. Retina 2002;22:471-7.
54. Allikmets R, Dean D. Bringing age-related macular degeneration into focus. Nat Genet 2008;40:820-1.
55. Chen J, Connor KM, Smith LE. Overstaying their welcome: defective CX3CR1 microglia eyed in macular degeneration. J Clin Invest 2007;117:2758-62.
56. Larrayouz IM, Huang JD, Lee JW, Pascual I, Rodriguez IR. 7-ketocholesterol-induced inslammation: involvement of multiple kinase signaling pathways via NFkB but independetly of reactive oxygen species formation. Invest Ophthalmol Vis Sci 2010;51:4942-55.
57. Moreira EF, Larrayoz IM, Lee JW, Rodriguez IR. 7-ketocholesterol is present in lipid deposits in the primate retina: potential implication in the induction of VEGF and CNV formation. Invest Ophthalmol Vis Sci 2009;50:523-32.
58. Dasari B, Prasanthi JR, Marwarha G, Singh BB, Ghribi O. The oxysterol 27-hydroxycholesterol increase β-amyloid and oxidative stress in retinal pigment epithelial cells. BMC Ophthalmol 2010;10:22.
59. Edwards AO, Ritter R III, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-4.
60. Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys I, de Maat MP, et al. Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 2006;296:301-9.
61. Rodri{dotless}guez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, Lopez-Trascasa M, Sanchez-Corral P. The human complement factor H: functional roles, genetic variations and disease associations. Mol Immunol 2004;41:355-67.
62. Oksjoki R, Jarva H, Kovanen PT, Laine P, Meri S, Pentikainen MO. Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation Arterioscler Thromb Vasc Biol 2003;23:630-6.
63. Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-21.
64. Hakobyan S, Harris CL, van der Berg CW, Fernandez-Alonso MC, de Jorge EG, de Cordoba SR, et al. Complement factor H binds to denaturated rather than to native pentametric C-reactive protein. J Biol Chem 2008; 283:30451-60.
65. Deangelis MM, Silveira AC, Carr EA, Kim IK. Genetics of agerelated macular degeneration: current concepts, future directions. Semin Ophthalmol 2011;26:77-93.
66. Lederman M, Weiss A, Chowers I. Association of neovascular age-related macular degeneration with specific gene expression patterns in peripheral white blood cells. Invest Ophthal Vis Sci 2010;51:53-8.
67. Cederholm A, Frostegard J. Annexin A5 in cardiovascular disease and systemic lupus erythematosus. Immunology 2005;210:761-8.
68. Rayborn Me, Sakaguchi H, Shadrach KG, Crabb JW, Hollyfield JG. Annexins in Bruch's membrane and drusen. Adv Exp Med Biol 2006;572:75-8.
69. Degn SE, Jensenius JC, Thiel S. Disease-causing mutations in genes of the complement system. Am J Hum Genet 2011;68:689-705.
70. Colak E, Kosanovic-Jakovic N, Zoric L, Radosavljevic A, Stankovic S, Majkic-Singh N. The association of lipoprotein parameters and C-reactive protein in patients with age-related macular degeneration. Ophthalmic Res 2011;46:125-32.
71. Schaumberg DA, Christen WG, Buring JE, Glynn RJ, Rifai N, Ridker PM. High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch Ophthalmol 2007;125:300-5.
72. Hong T, Tan AG, Mithchell P, Wang JJ. A review and meta-analysis of the association between C-reactive protein and age-related macular degeneration. Surv Ophthalmol 2011;56:184-94.
73. De Jong PT, Boekhoorn SS, Vingerling JR, Witteman JCM, Hofman A. C-reactive protein and incident aging macular disease (AMD): The Rotterdam Study. Invest Ophthalmol Vis Sci 2005;46:E-Abstract 2379.
74. Kikuchi M, Nakamura M, Ishikawa K, Suzuki T, Nishihara H, Yamakoshi T, et al. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration. Ophthalmol 2007;114:1722-7.
75. Boey PY, Tay WTT, Lamoureux E, Tai S, Mitchell P, Wang JJ, et al. C-Reactive protein and age-related macular degeneration and cataract: The Singapore Malay eye study. Invest Ophthalmol Vis Sci 2010;51:1880-5.
76. Pasceri V, Chang J, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4.
77. Verma S, Badiwala MV, Weisel RD, Li SH, Fedak PWM, Li RK, Mickle DAG. C-reactive protein upregulates the NF-κB signaling pathwayin saphenous vein endothelial cells: implications for atherosclerosis and restenosis. J Thorac Cardiovasc Surg 2003;126:1886-91.
78. Qamirani E, Ren Y, Kuo L, Hein TW. C-reactive protein inhibits endothelium-dependent NO-mediated dilation in coronary arterioles by activating p38 kinase and NAD(P)H oxidase. Arterioscler Thromb Vasc Biol 2005;25:995-1001.
79. Fichtlscherer S, Breuer S, Schachinger V, Dimmeler S, Zeiher AM. C-reactive protein levels determine systemic nitric oxide bioavailability in patients with coronary artery disease. Eur Heart J 2004;25:1412-8.
80. Wassmann S, Ribaudo N, Faul A, Laufs U, Bohm M, Nickenig G. Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels < 130 mg/ dL. Am J Cardiol 2004;93:84-8.
81. Zoric L, Kosanovic-Jakovic N, Colak E, Radosavljevic A, Jaksic V, Stevic S. Oksidativni stres u sklopu faktora rizika od nastanka i razvoja senilne degeneracije makule. Vojnosanit pregl 2008;65:313-8
82. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.
83. Chang MK, Binder CJ, Torzewski M, Witzum JL. C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a commom ligand:phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U.S.A. 2002;99:13043-8.
84. Scholl HPN, Charbel Issa P, Walier M, Janzer S, Polloh-Kopp B, Börncke F et al. Systemic complement activation in agerelated macular degeneration. PloS ONE 2008;3:e2593.
85. Choroid. Available at: http://en.wikipedia.org/wiki/Choroid. Accessed: November 25, 2011.
86. Retina. Available at: http://en.wikipedia.org/wiki/Retina. Accessed: November 25, 2011.
87. Retinal_pigmented_epithelium. Available at: http:// en.wikipedia.org/wiki/Retinal_pigmented_epithelium. Accessed: November 25, 2011.
88. Fovea_centralis. Available at: http://en.wikipedia.org/wiki/ Fovea_centralis. Accessed: November 25, 2011.
89. Macula_of_retina. Available at: http://en.wikipedia.org/ wiki/Macula_of_retina. Accessed: November 25, 2011.
90. Sclera. Available at: http://en.wikipedia.org/wiki/Sclera. Accessed: November 25, 2011.
91. Eye. Available at: http://en.wikipedia.org/wiki/Eye. Accessed: November 25, 2011.